Visit of His Excellency Dr. Nizar Mahmoud Mahidat to the company's headquarters

The Jordanian Sweden Company was honored by the visit of His Excellency Dr. Nizar Mahmoud Hmaidat to the company headquarter.

Dr. Nizar Mahmoud Hmaidat, the Director General of the Jordan Food and Drug Administration (JFDA), revealed that the JFDA has recently included about 150 drug items in its list of medications for achieving drug security. These items will be given priority for registration, inspection, and necessary technical consultations when their files are submitted. This move aims to encourage local drug manufacturers and warehouses to submit these drug files.

During a field visit to the Jordanian Sweden Company for Medical Products and Sterilization (JOSWE), Hmaidat added that the JFDA is reviewing the regulations related to changes in registered drugs, specifically regarding the approval of active ingredient manufacturers. The goal is to increase the number of sources for active pharmaceutical ingredients from three to five sources from various countries, ensuring their availability at a reasonable cost for local manufacturers. This will enhance drug security and support the national economy.

Hmaidat praised the company for being one of the distinguished national pharmaceutical manufacturers that has significantly contributed to the pharmaceutical and healthcare sectors. He emphasized that the JFDA is working diligently to implement royal directives to support the pharmaceutical industry and simplify procedures in various areas, particularly in boosting exports and overcoming challenges. He also highlighted the importance of maintaining the leading position of the pharmaceutical industry, which enjoys a distinguished reputation and ranks second in national exports.

Dr. Asaad Shahin, representing the General Manager of the Jordanian Sweden Company for Medical Products and Sterilization (JOSWE), Dr. Ali Shahin, welcomed Dr. Hmaidat and the accompanying delegation. He pointed out the technical support provided by the JFDA to the pharmaceutical industry and noted that the JFDA's excellence and development reflect positively on the pharmaceutical industry's progress, as it is a partner in the success achieved by this sector.

Dr. Arwa Mohamed Shahin, Director of Manufacturing Operations, mentioned that the presence of the JFDA at the company is an indicator of interest and care for the Jordanian pharmaceutical industry. She expressed pride in the factory's efforts, which reflect the national vision for an independent Jordanian industry. She also highlighted the pride of being part of this collaborative network and working under the JFDA's umbrella, which is a trusted guardian of the Jordanian pharmaceutical industry. The JFDA establishes frameworks, laws, and regulations that impact the quality of Jordanian medicine and is committed to ensuring the continued growth of the Jordanian pharmaceutical industry.

She emphasized the commitment to applying all relevant laws and regulations and striving to develop and improve the efficiencies and methods related to manufacturing, research, and development to provide pharmaceutical alternatives for the local market and export markets. She pointed out that without the JFDA's attention and the efforts of workers, inspectors, and technicians who are aware of and adapt to new requirements and regulations, the industry could not overcome the ongoing and evolving challenges.

Dr. Suzanne Obeid, Technical Director and Director of Regulatory Affairs, noted that the company produces over 200 drug items, exporting to 20 Arab, European, and other international markets. She commended the JFDA for its development and its alignment with the latest global standards. She praised the continuous acceleration and simplification of drug registration processes and related procedures while ensuring drug safety and quality.

She also appreciated the establishment of the scientific consultation and new regulatory services recently introduced by the JFDA, including the revised drug examination system, which separates analysis from registration and accelerates the registration of locally produced drugs for export purposes, and the drug security instructions.

The visit was part of the JFDA’s regular field visits to monitor local manufacturing processes, assess needs and suggestions, and explore possible support on the ground.